Last reviewed · How we verify
FE203799 GLP-2 analogue — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
FE203799 GLP-2 analogue (FE203799 GLP-2 analogue) — GlyPharma Therapeutics.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| FE203799 GLP-2 analogue TARGET | FE203799 GLP-2 analogue | GlyPharma Therapeutics | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- FE203799 GLP-2 analogue CI watch — RSS
- FE203799 GLP-2 analogue CI watch — Atom
- FE203799 GLP-2 analogue CI watch — JSON
- FE203799 GLP-2 analogue alone — RSS
Cite this brief
Drug Landscape (2026). FE203799 GLP-2 analogue — Competitive Intelligence Brief. https://druglandscape.com/ci/fe203799-glp-2-analogue. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab